Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second international treatment protocol for hemophagocytic lymphohistiocytosis (HLH)
2006-002391-17Phase 4Active
- Sponsor
- ARNAS Civico Di Cristina Benfratelli
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etoposide, dexamethasone and cyclosporine in haemophagocytic lymphohistiocytosis (HLH), sponsored by ARNAS Civico Di Cristina Benfratelli. Primary endpoints: Survival at 2 months and Survival at 5 years. Started Mar 2012; status: active.
02
Drugs
etoposidedexamethasonecyclosporine
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on 2006-002391-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002391-17.